“Descriptive Comparison of Rebound Progression Reported in the Included Studies” is Appropriate
Global Journal of Medical Research · 07.08.2026
DOI: 10.34257/gjmrf259224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Journal of Medical Research, online erschienen am 07.08.2026. Verfasst von Dr. Mohammad Mizanur Rahman. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The rise in myopia around the world has led to the widespread use of evidence-based methods to control it. However, finding the best time to stop treatment is still a big clinical problem because of worries about rebound progression after treatment stops. The goal of this systematic review and meta-analysis was to look at the effects of stopping myopia control treatments and to find out what factors are linked to safe cessation.
Methods
We used predefined Boolean strategies to search PubMed, Scopus, Web of Science, and Google Scholar in a systematic way. This review followed the rules set out by PRISMA 2020. Randomized controlled trials and observational studies that looked at the effects of myopia control interventions after they were stopped were eligible. The main outcomes were changes in axial length and spherical equivalent refraction (SER). We did a random-effects meta-analysis and then looked at the results by age, type of intervention, and length of treatment.
Result
A total of 36 studies were included, with 28 (~4,850 total subjects; 78% of all studies) being appropriate for meta-analysis. When treatment for myopia control was stopped, the axial length of the eye grew by an average of +0.21 mm / year and the development of myopia grew by an average of +0.42 dioptres/year (both 95%CI 0.31-0.53, I²=72%). Across the included studies, atropine consistently demonstrated greater rebound progression following treatment cessation than optical interventions. The child’s age (under 12 years) and the length of treatment (under 2 years) were both linked to a faster worsening of myopia after treatment ended.
Conclusion
When deciding to stop myopia control for a single person, it is important to think about the clinically significant rebound progression that is likely to happen after treatment ends. Longer treatment duration and discontinuation at an older age were associated with greater post-treatment stability. When pharmacological therapy is used to treat myopia, the treatment should be slowly tapered off. There is a necessity for uniform guidelines for the cessation of treatment grounded in robust scientific evidence.
Zitieren
APA
Rahman, D. M. M. (2026). “Descriptive Comparison of Rebound Progression Reported in the Included Studies” is Appropriate. Global Journal of Medical Research. https://doi.org/10.34257/gjmrf259224
Vancouver
Rahman DMM. “Descriptive Comparison of Rebound Progression Reported in the Included Studies” is Appropriate. Global Journal of Medical Research. 2026. doi:10.34257/gjmrf259224
BibTeX
@article{Rahman2026,
author = {Rahman, Dr. Mohammad Mizanur},
title = {“Descriptive Comparison of Rebound Progression Reported in the Included Studies” is Appropriate},
journal = {Global Journal of Medical Research},
year = {2026},
doi = {10.34257/gjmrf259224}
}
EUVIMED